Payment overview · 2025
General Payments
$1,467.00
68 reported records · 16 companies
Healthcare provider profile · identity verified
David Andrew Johnston, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRYSON CITY, NC · NPI 1750674800
Verified facts
What the public records show
CMS Open Payments records show David Andrew Johnston, MD received $1,467.00 in general payments during 2025 across 68 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 300 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $266.60 | 18.2% | 9 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $217.93 | 14.9% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $189.19 | 12.9% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $159.05 | 10.8% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $148.45 | 10.1% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $126.59 | 8.6% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $87.98 | 6.0% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $51.63 | 3.5% | 3 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $41.62 | 2.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.62 | 2.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $34.38 | 2.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.98 | 2.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.30 | 1.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.85 | 1.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.52 | 1.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.31 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,467.00 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $217.93 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $184.13 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $148.45 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $133.76 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $122.11 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $120.55 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $120.55 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $107.29 | 5 | 2025 |
Source payment records
|
|||||
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $99.10 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $87.98 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $68.64 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.03 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $51.63 | 3 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $41.62 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $34.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 195 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 83 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 84 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 167 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 300 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 32 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
94 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
167 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
300 | 59 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 31 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 855 | 251 |
| Lisinopril | Lisinopril | 684 | 199 |
| Gabapentin | Gabapentin | 595 | 125 |
| Losartan Potassium | Losartan Potassium | 587 | 170 |
| Levothyroxine Sodium | Levothyroxine Sodium | 550 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 510 | 152 |
| Omeprazole | Omeprazole | 451 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 421 | 118 |
| Hydrochlorothiazide | Hydrochlorothiazide | 416 | 118 |
| Meloxicam | Meloxicam | 402 | 109 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 370 | 97 |
| Trazodone Hcl | Trazodone Hcl | 353 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 339 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 326 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 318 | 99 |
| Tizanidine Hcl | Tizanidine Hcl | 315 | 79 |
| Ozempic | Semaglutide | 300 | 59 |
| Furosemide | Furosemide | 270 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 262 | 75 |
| Metformin Hcl | Metformin Hcl | 261 | 79 |
| Pravastatin Sodium | Pravastatin Sodium | 250 | 67 |
| Allopurinol | Allopurinol | 241 | 63 |
| Potassium Chloride | Potassium Chloride | 236 | 62 |
| Montelukast Sodium | Montelukast Sodium | 231 | 66 |
| Sertraline Hcl | Sertraline Hcl | 222 | 67 |
| Fluticasone Propionate | Fluticasone Propionate | 205 | 57 |
| Eliquis | Apixaban | 195 | 53 |
| Carvedilol | Carvedilol | 186 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 180 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 177 | 46 |
| Metformin Hcl Er | Metformin Hcl | 176 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 171 | 40 |
| Mounjaro | Tirzepatide | 167 | 24 |
| Famotidine | Famotidine | 161 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 48 |
| Alprazolam | Alprazolam | 149 | 19 |
| Prednisone | Prednisone | 149 | 79 |
| Simvastatin | Simvastatin | 138 | 43 |
| Pregabalin | Pregabalin | 127 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 126 | 30 |
| Glipizide | Glipizide | 125 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 125 | 31 |
| Lorazepam | Lorazepam | 123 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 119 | 36 |
| Temazepam | Temazepam | 116 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 113 | 32 |
| Alendronate Sodium | Alendronate Sodium | 109 | 35 |
| Cephalexin | Cephalexin | 108 | 59 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 28 |
| Spironolactone | Spironolactone | 104 | 36 |
| Finasteride | Finasteride | 102 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 25 |
| Tramadol Hcl | Tramadol Hcl | 98 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 98 | 58 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 20 |
| Xarelto | Rivaroxaban | 94 | 24 |
| Celecoxib | Celecoxib | 91 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 13 |
| Jardiance | Empagliflozin | 84 | 23 |
| Farxiga | Dapagliflozin Propanediol | 83 | 23 |
| Azithromycin | Azithromycin | 82 | 57 |
| Clonazepam | Clonazepam | 81 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 57 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 17 |
| Sucralfate | Sucralfate | 76 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 75 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 73 | 11 |
| Ibuprofen | Ibuprofen | 70 | 18 |
| Buspirone Hcl | Buspirone Hcl | 68 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 15 |
| Lansoprazole | Lansoprazole | 62 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 14 |
| Atenolol | Atenolol | 61 | 20 |
| Meclizine Hcl | Meclizine Hcl | 61 | 23 |
| Ondansetron Odt | Ondansetron | 61 | 30 |
| Donepezil Hcl | Donepezil Hcl | 59 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 16 |
| Nitroglycerin | Nitroglycerin | 58 | 24 |
| Novolog Flexpen | Insulin Aspart | 58 | 20 |
| Linzess | Linaclotide | 57 | 16 |
| Nystatin | Nystatin | 56 | 26 |
| Bupropion Xl | Bupropion Hcl | 54 | 18 |
| Entresto | Sacubitril/Valsartan | 54 | 14 |
| Memantine Hcl | Memantine Hcl | 54 | 16 |
| Synthroid | Levothyroxine Sodium | 54 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 45 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 53 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 50 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 15 |
| Ketoconazole | Ketoconazole | 48 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 18 |
| Ezetimibe | Ezetimibe | 47 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | suppressed |
| Fluconazole | Fluconazole | 44 | 31 |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 39 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 44 | 11 |
| Warfarin Sodium | Warfarin Sodium | 43 | 13 |
| Amoxicillin | Amoxicillin | 41 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 25 |
| Propranolol Hcl | Propranolol Hcl | 40 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 11 |
| Lovastatin | Lovastatin | 38 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 12 |
| Clonidine Hcl | Clonidine Hcl | 36 | 13 |
| Chlorthalidone | Chlorthalidone | 35 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | 11 |
| Promethazine Hcl | Promethazine Hcl | 33 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 31 |
| Ramelteon | Ramelteon | 32 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 32 | suppressed |
| Colchicine | Colchicine | 31 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 11 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Lactulose | Lactulose | 27 | 14 |
| Naproxen | Naproxen | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Diazepam | Diazepam | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 21 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 13 |
| Cilostazol | Cilostazol | 24 | suppressed |
| Ibu | Ibuprofen | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Trulance | Plecanatide | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 14 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,467.00 · 68 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, Kerendia, MOUNJARO, NEXIUM, NURTEC ODT, Ohtuvayre, Ozempic, PAXLOVID, Quviviq, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error